Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination.

Panou, E; Nikolaou, V; Marinos, L; Kallambou, S; Sidiropoulou, P; Gerochristou, M; Stratigos, A

Panou, E; Nikolaou, V; Marinos, L; Kallambou, S; Sidiropoulou, P; Gerochristou, M; Stratigos, A.

Afiliação

Panou E; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.
Nikolaou V; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.
Marinos L; Department of Hemopathology, Evangelismos Hospital, Athens, Greece.
Kallambou S; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.
Sidiropoulou P; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.
Gerochristou M; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.
Stratigos A; 1st Dermatology Department, Andreas Syggros Hospital for Skin Diseases, National & Kapodestrian University of Athens Medical Schoool, Athens, Greece.

J Eur Acad Dermatol Venereol ; 36(2): e91-e93, 2022 Feb.

Article em En | MEDLINE | ID: mdl-34628691

Assuntos

COVID-19; Linfoma Cutâneo de Células T; Neoplasias Cutâneas; Vacinas contra COVID-19; Humanos; SARS-CoV-2; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Linfoma Cutâneo de Células T / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google